These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26254496)

  • 1. Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs.
    Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ;
    Int J Drug Policy; 2015 Nov; 26(11):1039-40. PubMed ID: 26254496
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs.
    Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ;
    Int J Drug Policy; 2015 Oct; 26(10):893-8. PubMed ID: 26254497
    [No Abstract]   [Full Text] [Related]  

  • 3. Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses.
    Lazarus JV; Safreed-Harmon K; Stumo SR; Jauffret-Roustide M; Maticic M; Reic T; Schatz E; Tallada J; Harris M;
    Int J Drug Policy; 2017 Sep; 47():47-50. PubMed ID: 28689856
    [No Abstract]   [Full Text] [Related]  

  • 4. New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series.
    Hickman M; Grebely J; Bruneau J; Coffin P; Degenhardt L; Hutchinson S; Larney S; Martin N; Treloar C; Vickerman P
    Addiction; 2017 Jul; 112(7):1126-1127. PubMed ID: 28586551
    [No Abstract]   [Full Text] [Related]  

  • 5. Access to hepatitis C care for people who inject drugs and people in prisons.
    Oru E; Verster A
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):662-663. PubMed ID: 31362917
    [No Abstract]   [Full Text] [Related]  

  • 6. Moving the agenda forward: the prevention and management of hepatitis C virus infection among people who inject drugs.
    Grebely J; Bruggmann P; Backmund M; Dore GJ
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S29-31. PubMed ID: 23884062
    [No Abstract]   [Full Text] [Related]  

  • 7. Agent, host, and environment: hepatitis C virus in people who inject drugs.
    Hagan H
    J Infect Dis; 2011 Dec; 204(12):1819-21. PubMed ID: 22013223
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs.
    Hickman M; Martin NK; Huxtable R
    Addiction; 2017 Feb; 112(2):201-203. PubMed ID: 27514647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The physical health of people who inject drugs: complexities, challenges, and continuity.
    Cornford C; Close H
    Br J Gen Pract; 2016 Jun; 66(647):286-7. PubMed ID: 27231287
    [No Abstract]   [Full Text] [Related]  

  • 11. Eradication of hepatitis C infection: the importance of targeting people who inject drugs.
    Hellard M; Doyle JS; Sacks-Davis R; Thompson AJ; McBryde E
    Hepatology; 2014 Feb; 59(2):366-9. PubMed ID: 23873507
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment.
    Bouscaillou J; Champagnat J; Luhmann N; Avril E; Inaridze I; Miollany V; Labartkava K; Kirtadze I; Butsashvili M; Kamkamidze G; Pataut D
    Int J Drug Policy; 2014 Sep; 25(5):871-8. PubMed ID: 24529802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs.
    Harris M; Rhodes T
    Addiction; 2012 Jun; 107(6):1090-6. PubMed ID: 22151433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment as prevention: the breaking of taboos is required in the fight against hepatitis C among people who inject drugs.
    Bruggmann P
    Hepatology; 2013 Nov; 58(5):1523-5. PubMed ID: 23728921
    [No Abstract]   [Full Text] [Related]  

  • 15. Social inclusion and hepatitis C: exploring new possibilities for prevention.
    Treloar C; Valentine K; Fraser S
    Expert Rev Anti Infect Ther; 2011 Apr; 9(4):397-404. PubMed ID: 21504397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary health care for people who inject drugs in low and middle income countries.
    Myers BJ
    Int J Drug Policy; 2012 Mar; 23(2):105-6. PubMed ID: 22030256
    [No Abstract]   [Full Text] [Related]  

  • 17. HCV in people who inject drugs: a neglected epidemic.
    Sarna A; Panda S
    Lancet Infect Dis; 2015 Jan; 15(1):4-5. PubMed ID: 25486850
    [No Abstract]   [Full Text] [Related]  

  • 18. Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.
    Falla AM; Veldhuijzen IK; Ahmad AA; Levi M; Hendrik Richardus J
    Eur J Public Health; 2017 Apr; 27(2):302-306. PubMed ID: 27542982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries.
    Reimer J; Schulte B; Castells X; Schafer I; Polywka S; Hedrich D; Wiessing L; Haasen C; Backmund M; Krausz M
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S373-8. PubMed ID: 15768351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.